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Abstract
Multiple myeloma is a post-germinal center B-cell neoplasm, characterized by the proliferation of malignant bone
marrow plasma cells, whose survival and proliferation is sustained by growth factors and cytokines present in the bone
marrow microenvironment. Among them, IL-6 triggers the signal downstream of its receptor, leading to the activation
of the JAK/STAT pathway. The atypical GTPase RhoU lays downstream of STAT3 transcription factor and could be
responsible for mediating its effects on cytoskeleton dynamics. Here we demonstrate that RHOU is heterogeneously
expressed in primary multiple myeloma cells and signiﬁcantly modulated with disease progression. At the mRNA level,
RHOU expression in myeloma patients correlated with the expression of STAT3 and its targets MIR21 and SOCS3. Also,
IL-6 stimulation of human myeloma cell lines up-regulated RHOU through STAT3 activation. On the other hand, RhoU
silencing led to a decrease in cell migration with the accumulation of actin stress ﬁbers, together with a decrease in
cyclin D2 expression and in cell cycle progression. Furthermore, we found that even though lenalidomide positively
regulated RhoU expression leading to higher cell migration rates, it actually led to cell cycle arrest probably through a
p21 dependent mechanism. Lenalidomide treatment in combination with RhoU silencing determined a loss of
cytoskeletal organization inhibiting cell migration, and a further increase in the percentage of cells in a resting phase.
These results unravel a role for RhoU not only in regulating the migratory features of malignant plasma cells, but also
in controlling cell cycle progression.
Introduction
Multiple myeloma (MM) is a post-Germinal Center
cancer characterized by a multifocal proliferation of clo-
nal, long-lived plasma cells (PCs) within the bone marrow
(BM)1. This multistep malignancy is preceded by an age-
progressive premalignant condition called monoclonal
gammopathy of undetermined signiﬁcance (MGUS)1–3.
Some patients pass through a phase called smoldering
myeloma (sMM), in which some of the diagnostic criteria
for MM are met but there are no clinical manifestations2.
In early stages, MM cells like normal long-lived PCs are
highly dependent on the BM microenvironment that
activates multiple pathways, protecting these cells from
apoptosis4. IL-6, primarily produced by BM stromal cells
(BMSCs), is the best characterized MM growth factor and
is highly responsible for cell homing, seeding, prolifera-
tion, and survival through the activation of the JAK/STAT
pathway2,4.
The Rho family of small guanosine triphosphatases
(GTPases) forms part of the Ras super-family. These
GTPases share a common biochemical mechanism, acting
as molecular switches to transduce the signal downstream
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to their effectors5. To note, the Ras family has been pro-
ven to profoundly inﬂuence cell growth and activating
mutations of Ras are associated with cancer6. In contrast,
Rho GTPases are hardly ever found mutated but often
display altered activity in malignant cells when compared
to healthy counterparts7. Rho GTPases are potent reg-
ulators of cytoskeleton dynamics and of the actin ﬁlament
system, thereby affecting the morphologic and migratory
properties of cells8. Due to their important roles in con-
trolling these cellular processes, deregulated Rho GTPases
could be at the basis of many tumorigenic events.
The RhoU/V sub-family is particularly interesting due
to its unique domain organization. Both members of this
family, RhoU and RhoV, have an N-terminal proline-rich
domain that is not present in any other Rho GTPase and
that enables them to permanently bind to their effec-
tors7,9. RhoU has no detectable GTPase activity but its
very high intrinsic guanine nucleotide exchange activity is
likely to ensure that the protein is predominantly in the
GTP-loaded conformation10. It is encoded by the RHOU
gene at 1q42.13 and its expression is mainly controlled at
the RNA level downstream of Wnt-1 and STAT3 activa-
tion and it might mediate the effects of these signaling
pathways in regulating cell morphology, cytoskeletal
organization, and proliferation11. Also, different levels of
this GTPase might lead to diverse outcomes in cell
morphology. It is known that during epithelial-
mesenchymal transition of neural crest cells, high levels
of RhoU inﬂuence cell polarity and migration while low
levels are required for cell adhesion12. While typical Rho
proteins, such as Cdc42 and Rac1 that share signiﬁcant
sequence homology with RhoU, have an established role
in cancer, very little is known about RhoU in tumor-
igenesis in particular in hematologic malignancies7. Since
RhoU can alter cell adhesion, actin dynamics, and cell
motility, we aimed at testing if this protein could mediate
these cellular features in myeloma cells and if changes in
its expression, and thus activity, might lead to BM niches
remodeling.
Materials and methods
Patient samples and healthy donors
PCs were puriﬁed from BM samples using CD138
immunomagnetic microbeads (MidiMACS system, Mil-
tenyi Biotec, Auburn, CA) and the purity of the positively
selected PCs was >90% in all cases. Gene expression
proﬁles (GEP) were investigated in a panel of 268 patients
included in two different datasets and representative of all
the major forms of PC dyscrasia: a proprietary dataset at
NCBI Gene Expression Omnibus repository (accession
#GSE66293) previously proﬁled by us (4 normal controls
and 129 MM patients)13,14; and a publicly available data
set including ﬁve normal controls, 20 MGUS, 33 SMM,
and 41 MM patients (accession #GSE47552)15. The
cohort consists of newly-diagnosed patients. The pro-
prietary 129 MM tumors (accession #GSE66293)
employed for the study were representative of the major
molecular characteristics of the disease and stratiﬁed
according the TC classiﬁcation16,17. Deletions of 17p13,
13q14 and gain of 1q were also evaluated by FISH18.
Procedures followed the rules indicated in the declaration
of Helsinki. The internal Institutional Board approved the
use of human material.
Cell lines
INA-6 cell line was a kind gift from Dr. Martin Gra-
matzki (University of Kiel, Germany). U266, H929, RPMI-
8226, and HS-5 were purchased from ATCC-LGC Stan-
dards (Milan, Italy). SaMMi cell line was generated in our
laboratory19. Cell cultures were kept under controlled
atmosphere at 37 °C in the presence of 5% CO2 and were
periodically checked for Mycoplasma contamination.
SiRNA transfection
U266 cells were transfected with Amaxa Nucleofector®
Kit C (Lonza, USA) and 100 pmol of RhoU siRNA
(Dharmacon ON-TARGETplus RHOU siRNA, Euro-
clone, Italy) or 100 pmol of Scrambled (Dharmacon ON-
TARGETplus non-targeting siRNA, Euroclone, Italy)
according to the manufacturer’s instruction.
Chemicals
2× 106 cells were cultured in 2ml of favorite medium,
stimulated with 10 ng of IL-6 (ImmunoTools, Germany)
and samples were collected at different time points. Cell
lines that are usually cultured in medium supplemented
with IL-6 were starved from this cytokine for 12 h pre-
vious to stimulus.
Stattic (Selleckchem, USA) was employed for 5 h at
different doses to inhibit STAT3 and then IL-6 was added
or not to the cells for 1 h. Cells were starved of IL-6 only
during the 6 h of treatment.
Lenalidomide (Selleckchem, USA) was used at different
doses for 4 or 24 h.
Transwell migration assay
5μmTranswell® Permeable Supports on 24 well plates
(Corning, USA) were used according to manufacturer
instructions. Six hundred microliter non-supplemented
medium+ 0.1%BSA were added to the bottom of multi-
well plate and 50 μL of the same mix were added on top of
the transwell insert. 4× 105 cells were washed with HBSS
buffer and then resuspended in 50 μL of recommended
medium+ 0.1%BSA and added to the top well insert.
Plates were incubated for 20min and then IL-6 stimulus
(10 ng) or MSC culture medium (from 24 h MSC culture)
was carefully added to the bottom well. IL-6 or MSC
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culture medium was not added to control wells. Plates
were incubator for 6 h before collection.
Immunohistochemistry (IHC)
IHC was performed on 4 μm-thick formalin-ﬁxed,
parafﬁn-embedded sections of BM biopsies of 1 healthy
and 8 MGUS using anti-RhoU (HPA049592, Sigma-
Aldrich, USA) and anti-IRF4 (HPA002038, Sigma-
Aldrich, USA) monoclonal primary antibodies. Fifteen-
miilimeter biopsies were stained with anti-RhoU and
zones with a clearly abundant plasmacytosis were used in
evaluating RhoU positivity. All sections were processed
using the sensitive Bond Polymer Reﬁne Detection kit, a
biotin-free, polymeric horseradish peroxidase–linker
antibody conjugate system, in an automated immunos-
tainer (Bond maX, Menarini, Italy). Appropriate positive
and negative controls were run concurrently. RhoU
immunostain was semiquantitatively scored in a four-
tiered scale, as follows: score 0= negative staining; score
1=weak positivity staining; score 2=moderate positivity
staining; score 3= strong positive staining. Immunohis-
tochemical reactions were independently scored by two
investigators (agreement k> 0.8).
Immunoﬂuorescence (IF)
5× 104 cells were seeded on polylysine-coated glass
slides and incubated at 37 °C for 1 h to let them adhere to
the polylysine, ﬁxed with formaldehyde 3.7%, permeabi-
lized with Triton 0.1% and blocked with BSA 3%. Samples
were then stained with Phalloidin Alexa Fluor 594 (Invi-
trogen, USA) for 30’, mounted in Vectashield mounting
medium with DAPI (4′,6-diamidino-2-phenylindole)
(Vector Laboratories, USA) and analyzed using ZEISS
LSM700 confocal microscope with 63× magniﬁcation
objective. Images were analyzed with ImageJ software.
Results
Rho GTPases display altered expression in MM PCs
We have assessed the expression of the Rho GTPase
family members in PCs from BM biopsies of MM patients
and in normal BM PCs from healthy donors, using the
gene expression proﬁling (GEP) of 129 MM patient
samples at diagnosis and four healthy controls included in
the proprietary GEO data set GSE66293. We found that
Rho GTPase family members are differently expressed in
MM PCs when compared to healthy PCs (Fig. 1a). More
precisely, 12 (CDC42, RAC1, RAC2, RHOA, RHOBTB1,
RHOD, RHOF, RHOG, RHOH, RHOU, RHOV, and RND1)
out of the 21 GTPases analyzed, were expressed at sig-
niﬁcantly lower levels in MM when compared to healthy
controls (p< 0.05).
RhoU is heterogeneously expressed in different steps of
MM progression
Next, we combined the data available in two GEP data
sets (#GSE66293 and #GSE47552) as previously descri-
bed13 and found that RHOU expression is signiﬁcantly
and negatively modulated with disease progression, being
over-expressed in BM PCs from MGUS patients and
down-modulated in BM PCs from most MM patients (Fig.
1b left panel). However, we found a large heterogeneity in
RHOU expression, with several patients showing high
transcript levels even in late stages. Therefore, we divided
patients in three groups according to low (<mean—2 SD
of healthy controls), intermediate (=mean± 2 SD of
healthy controls), and high (>mean+ 2 SD of healthy
controls) expression. Along with disease progression there
was an evident decrease in the percentage of patients that
fell in the group with intermediate RHOU expression (Fig.
1b right panel) and an increase in heterogeneity. In MM
in particular, there were three distinct groups of patients:
Fig. 1 RhoU is heterogeneously expressed in MM. a Rho GTPase family members’ expression in healthy and MM PCs. Box plot showing mean ±
SD of healthy PCs from four donors (red) and mean ± SD of MM PCs from 129 MM patients at diagnosis (black). In the x axis are all the members of
the Rho GTPase family in alphabetical order. Student’s t test *p < 0.05; **p < 0.01; ***p < 0.001 when compared to healthy PCs. b left: RHOU expression
in the different steps of MM progression. Box plot showing mean ± SD of healthy PCs from nine donors, MGUS PCs from 20 patients, sMM PCs from
33 patients and MM PCs from 170 patients at diagnosis. Student’s t test: NS non signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
(*compared to healthy; #compared to MGUS; $compared to SMM). right: Bar chart showing the percentage of patients for each step of the disease
that fall in the diverse groups of RHOU expression. Patients were divided in three groups with low (<mean−2 SD of healthy controls), intermediate,
and high (>mean + 2 SD of healthy controls) RHOU expression. Chi square test of patients’ distribution: ****p < 0.0001 when compared to healthy. c
RhoU expression in BM biopsies of a healthy donor and a representative MGUS patient. PCs in the samples are indicated with black arrows. Nucleuses
of PCs are positive for IRF4 staining and are therefore red. d IHC staining showing low (MM score 1), intermediate (MM score 2) and high (MM score 3)
positivity for RhoU staining in BM biopsies from representative MM patients. c and d Original magniﬁcation x60; inset with x5 digital zoom; scale bar
= 100 μm. e Bar charts showing qRT-PCR RHOU/GAPDH ratio values in PCs puriﬁed from 20 MM patient’s biopsies. Mean ± SD of technical triplicates
is shown for each samples. f Immunoblot and densitometry of RhoU/Tubulin in PC lysates from 39 MM patient’s biopsies. g Aligned dot plot with
RHOU expression in patients that fall in the standard risk (TC1 and TC2) and high risk (TC3, TC4, and TC5) groups. Mean expression in each group is
marked with a bar. p value was calculated by Student’s t test. h Bar chart representing the percentage of patients from each of the three groups with
low (<mean—2 SD of healthy controls), intermediate, and high (>mean + 2 SD of healthy controls) RHOU expression that exhibit a particular genetic
alteration. Student’s t test for trend *p < 0.05; **p < 0.01; ****p < 0.0001. i Aligned dot plot with RHOU expression in patients that don’t present any
unfavorable cytogenetic alterations (none), that present unfavorable cytogenetic alterations but not 1q gain (other), that present only 1q gain, and
that present 1q gain combined with other unfavorable cytogenetic alterations. Student’s t test: NS non signiﬁcant; *p < 0.05
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42% with low, 47% with intermediate, and 11% with high
RHOU expression.
To further examine RhoU expression we performed
IHC analysis in an independent panel of patients includ-
ing 8 MGUS and 15 active MM. All MGUS patients’ PCs
showed a high intensity cytoplasmic staining for RhoU
when compared to healthy PCs (Fig. 1c). Also, PCs from
all MM patients showed positivity for RhoU staining and
were given a score based on the intensity. More precisely
20% showed weak (score 1), 40% moderate (score 2), and
40% high RhoU (score 3) positivity, consistent with the
heterogeneous levels of RHOU mRNA described above
(Fig. 1d). Cells with different scores seem to also have a
diverse localization of RhoU: in MM cells with score 1
RhoU had a dot-like localization in proximity of the
nucleus, which could represent the actin microtubule-
organizing center, whereas cells that scored 2 or 3 showed
a granular cytoplasmic and membrane localization. The
heterogeneous levels of RhoU in MM patients were also
validated by qRT-PCR (Fig. 1e) and Western Blot (Fig. 1f).
Next, we evaluated RHOU levels according to the major
molecular groups of MM patients based on the TC clas-
siﬁcation as previously described17. Patients were further
divided in two groups: standard risk patients that fall into
TC1 and TC2 groups (n= 64) and characterized by t
(11,14) (TC1) and hyperdiploidy (TC2) leading to cyclin
D1 expression, and high risk patients that comprise TC3,
TC4, and TC5 groups (n= 65) characterized by cyclin D2
expression alone (TC3) and presence of t(4;14) (TC4) or
MAF translocations (TC5). The results show that patients
in the high risk group have signiﬁcantly higher levels of
RHOU expression (Fig. 1g), compared to TC1/TC2
patients. Furthermore, patients with high RHOU expres-
sion have a higher frequency of 1q gain, del(13), and t
(4;14) (Fig. 1h). Finally, since RHOU is located at 1q42 we
have divided the patients in four groups, without unfa-
vorable cytogenetic alterations (none), with unfavorable
cytogenetic alterations but without 1q gain (other), with
1q gain only, and with 1q gain plus unfavorable cytoge-
netic alterations, discovering that 1q gain alone is not
enough to cause a signiﬁcant increase in RHOU expres-
sion (Fig. 1i).
To better understand if RHOU expression could cor-
relate with patient survival we have used two datasets: one
with expression in untreated patients and overall survival
after Total Therapy 2 (TT2) and Total Therapy 3 (TT3)
regimens (#GSE2658)20–22, and another with expression
after several lines of therapy and overall survival after
Total Therapy 6 (TT6) (#GSE57317)23. We have divided
the patients from each dataset in RHOU expression
Fig. 2 Patients with high and low RHOU expression have different gene expression proﬁles. a Heat map of genes contributing to the core
enrichment in the “Cell Cycle” and “DNA Repair” gene sets detected by GSEA analyzing signiﬁcantly up-regulated genes (p-value≤ 0.05) in RHOU
quartile I versus IV (indicated in bold). Enrichment plots for b “Cell Cycle” and c “DNA Repair” gene sets. The green curves show the enrichment score
and reﬂect the degree to which each gene (black vertical lines) is represented at the bottom of the ranked gene list. d Cell cycle analysis based on PI
staining of SCR and siRNA RHOU cells 24 and 48 h after transfection. Data represents mean ± SD of three independent experiments. Student’s t test:
*p < 0.05; **p < 0.01. e Representative immunoblots from six samples from two independent experiments of RhoU and cyclin D2 expression 24 and
48 h after siRNA transfection, and densitometry of the mean expression of cyclin D2/GAPDH ± SD
Table 1 Gene set “Cell Cycle” was detected by GSEA as
signiﬁcantly up-regulated in RHOU quartile I versus IV
GSEA results summary
GeneSet Cell cycle
Genes ITGB3BP, NUP160, BTRC, POLE, ANAPC4,
KIF18A, POLA2, MCM8, APITD1, CCND2,
PSMA3, CEP290, ANAPC7, NUP43
Normalized Enrichment
Score (NES)
1.48
Nominal p-value 0.03
FDR 0.031
ITGB3BP overexpression induces apoptosis in cancer cells24; NUP160, NUP43,
KIF18A, BTRC, APITD1, and CEP290 are required for correct mitosis, centrosome
dynamics, and chromosome alignment25–30; POLE, POLA2, and MCM8 have
extremely important roles in DNA replication and genome stability31–33; ANAPC4
and ANAPC7 have emerging roles in differentiation control, genomic stability
and tumor suppression34; CCND2 enhances cell cycle progression and MM
proliferation35 and PSMA3 is part of the proteasome complex and essential for
protein degradation during cell cycle progression36.
Table 2 Gene set “DNA Repair” was detected by GSEA as
signiﬁcantly up-regulated in RHOU quartile I versus IV
GSEA results summary
GeneSet DNA repair
Genes NBN, REV1, POLR2K, POLE, DDB2, LIG3,
OGG1, ATM, RAD50, BRCA1
Normalized Enrichment
Score (NES)
1.60
Nominal p-value 0.00
FDR 0.00
These genes are extremely important since they encode for proteins essential in
a number of cellular pathways that maintain genomic stability, including DNA
damage-induced cell cycle checkpoint activation, DNA damage repair, protein
ubiquitination, chromatin remodeling, as well as transcriptional regulation and
apoptosis37–44.
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quartiles and compared the survival curves of the ﬁrst and
fourth quartiles. In TT2 or TT3 regimens there is a 50%
higher risk of death (hazard ratio= 1.50) for the patients
in the 4th quartile when compared to patients in the I
quartile (Supplementary Figure S1a and b). In TT6 regi-
men the risk of death increases to 612% (hazard ratio=
7.12) for patients in the IV quartile when compared to
patients in the I quartile (Supplementary Figure S1c and
d). These data suggest a positive correlation between high
RHOU levels and worse prognosis also after anti-
myeloma therapies. Whether or not its association with
poor outcomes can be linked to the combination of 1q
gain and other unfavorable cytogenetic alterations
remains to be investigated.
Patients with high and low RHOU expression have a
different GEP
To gain insights into the role of RHOU in MM, we
focused on our proprietary MM group (#GSE66293) due
to the absence of any bias related to sample molecular
characteristics, and looked for the gene expression sig-
nature associated with RHOU expression. Speciﬁcally, we
ranked patients in four classes based on RHOU expression
level. Next, by comparing the lowest (I quartile) with the
highest (IV quartile) RHOU expressing patients, we found
557 genes differentially expressed between the two groups
that appeared to be gradually modulated in the four
quartiles (Supplementary Table S1). Functional enrich-
ment analysis of the 557 deregulated genes using DAVID
Bioinformatics Resources 6.8 evidenced 12 signiﬁcantly
annotation clusters (ES> 1.3) and six signiﬁcantly enri-
ched pathways, among which cell cycle and DNA repair
(Supplementary Table S2). In addition, to conﬁrm the
correlation between RHOU and these pathways, we used
the Gene Set Enrichment Analysis (GSEA) to identify a
priori deﬁned sets of genes showing concordant mod-
ulation between patients with low and high RHOU
expression level. Notably, the cell cycle control and DNA
repair gene sets were found highly enriched in MM group
expressing lower (I quartile) RHOU levels (Fig. 2a-c).
RHOU clustered with 14 genes that regulate the cell
cycle and the mitotic process (Table 1). CCND2 was the
only gene in the list that positively correlated with RHOU
(Pearson’s r= 0.402; p-value= 7.193e-15) suggesting that
malignant PCs with high RHOU expression have
increased levels of cyclin D2 and a higher replication rate.
All the other genes responsible for cell cycle control and
DNA damage response had a negative correlation with
RHOU expression (Fig. 2b). RHOU also clustered with 10
DNA damage repair genes in the “DNA Repair” pathway
(Table 2). All the ten genes in the list negatively correlate
with RHOU expression (Fig. 2c).
Strikingly, in U266 cell line, the inhibition of RhoU by
siRNA resulted at 24 h in a slight but signiﬁcant accu-
mulation of cells in the G0/G1 phase and a decrease in
replicating S phase cells (Fig. 2d). The results were more
evident at 48 h with an increase in both sub G0/G1 and
G0/G1 phases and a decrease in both S and G2/M phases.
Since G1 to S phase transition is tightly regulated by the
expression of cyclin D2, we have analyzed this protein’s
expression after RhoU silencing and conﬁrmed a decrease
in its levels as early as 24 h after transfection; The
decrease in RhoU protein levels at these time points was
conﬁrmed by western blotting (Fig. 2e).
RHOU is overexpressed in IL-6-dependent MM cell lines
and is driven by the activation of STAT3
To better understand RHOU regulation in MM we have
investigated its expression on the GEP data (#GSE66293)
and on ﬁve MM cell lines available in our laboratory, two
IL-6 dependent (INA-6 and SaMMi), one that autocrinally
produces IL-6 (U266) and two IL-6 independent (H929
and RPMI-8226). GEP data relative to MM cell lines
shows that only INA-6, U266 and UTCM2 (a cell line that
also autocrinally produces IL-6) had high RHOU expres-
sion levels (Fig. 3a). We have also investigated RHOU
expression by qRT-PCR conﬁrming that RPMI-8226 and
H929 expressed RHOU at very low levels, while IL-6
dependent/autocrine cell lines over-expressed it (Fig. 3b).
To determine whether IL-6 stimulus could lead to an
up-regulation of RHOU expression cells were deprived
from this cytokine and subsequently stimulated. Samples
were collected at different time points (Fig. 3c). All three
IL-6-dependent cell lines up-regulated RHOU as early as
Fig. 3 RHOU expression in MM cell lines relies on IL-6 stimulus. a Bar chart showing RHOU expression assessed by GEP (#GSE66293) in MM cell
lines as compared to healthy PCs. b Bar chart showing RHOU expression in MM cell lines assessed by RT-PCR. Data represents normalized mean ± SD
of three independent samples of each cell line. c Time-course of RHOU expression after IL-6 stimulus showing a signiﬁcant increase in RHOU
expression as early as one hour after stimulus; time points before zero correspond to IL-6 starvation period. d Left: representative dot plot showing
intracytoplasmic RhoU staining in the CD45+ and CD45− populations of U266 cell line. Right: mean ± SD of four samples mean ﬂuorescence intensity
of intracytoplasmic RhoU staining in the CD45+ and CD45− populations of U266 cell line. e Time-course of RHOU expression after the addition of IL-6,
TNF-α, BMSCs’ conditioned medium or fresh unsupplemented medium. f Time-course showing the changes in RHOU expression after the addition of
HS-5 supplemented medium of starved and not starved cell lines. g Time-course showing the changes in RHOU expression after co-culture with HS-5
of starved and not starved cell lines. c, e, f, and g Data represents mean ± SD of six samples from at least two independent experiments normalized
over mean expression at time zero. Student’s t test: NS non signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001, when compared to time zero of untreated
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1 h after stimulus. In detail, 1 h after the addition of IL-6,
there was an increase in RHOU expression equal to 1.2
times-fold in U266, 1.7 times-fold in SaMMi, and 2.4
times-fold in INA-6. U266 might display the smallest
changes due to the fact that this cell line cannot be starved
from IL-6 since it autocrinally produces it.
Since CD45+ myeloma cells have increased JAK/STAT
activation45,46,, we have also studied the CD45+ and
CD45− U266 cell populations to further examine RhoU
expression in this context. Intracytoplasmic RhoU stain-
ing showed a mean ﬂuorescence intensity (MFI) of 822
and of 1878 in the CD45− and CD45+ cell populations,
respectively (Fig. 3d).
To verify if this effect was due to the speciﬁc activation
of the IL6R/STAT3 pathway, we stimulated cells also with
TNF-α, conditioned medium from BMSCs’ culture, or
unsupplemented fresh medium (Fig. 3e). The dynamics of
RHOU expression after the addition of BMSCs’ condi-
tioned medium or IL-6 stimulus were similar, while TNF-
α did not cause any signiﬁcant changes. Adding derived
media from HS-5 stromal cell line showed the same
results as IL-6 stimulus (Fig. 3f) and a really slow increase
in RHOU expression was obtained by co-culturing IL-
6 starved cell lines with HS-5 cells (Fig. 3g). However, the
co-culture on HS-5 cells of non-starved cells, with high
levels of RhoU, resulted in an actual decrease in RHOU
expression (Fig. 3g). These results may support the
hypothesis of a contact dependent down-modulation of
RHOU after cell adhesion, as previously observed in
neural crest cells47.
Interestingly, looking at GEP data from MM patients we
found a weak but signiﬁcant positive correlation between
RHOU and STAT3 expression. The analysis of STAT3
targets MIR21 and SOCS3 unraveled however a stronger
positive correlation with the expression of RHOU (Fig.
4a).
Next, to verify that STAT3 was the principal tran-
scriptional regulator of RHOU downstream of the IL-6R,
we inhibited STAT3 with stattic, a chemical inhibitor that
blocks STAT3 phosphorylation, dimerization, and nuclear
transition by speciﬁcally binding to its SH2 domain48.
Based on annexin V staining, a 6 h treatment with this
drug resulted in a slight but signiﬁcant increase in cell
death only at the highest doses for INA-6 cell line (Fig.
4b). Upon non-toxic doses of stattic treatment we
observed a dose-dependent decrease in RHOU expression,
while cells were less, if not able, to upregulate the GTPase
in response to IL-6 stimulus (Fig. 4c). Stattic treatment
also led to a dose dependent decrease in cell migration
that could rely on RHOU expression (Fig. 4d).
Lenalidomide treatment increases MM cell migration that
is overturned by RhoU inhibition
To better assess the effects of RhoU in MM cells we
have silenced it by transfecting cells with speciﬁc siRNA
particles. Scrambled non-targeting siRNA (SCR) was used
as control. RhoU silencing led to a clear decrease in JNK
activating phosphorylation, but did not seem to have an
effect on cell death nor on STAT3 activation (Fig. 5a left
panel). JNK1 is a target of RhoU, important for the
development of ﬁlopodia11. Therefore, an impairment in
its activation could explain the decreased migration cap-
ability of RhoU-targeting siRNA transfected cells (Fig. 5a
right panel). Furthermore, since IMIDs were shown to be
able to regulate the activation of classical Rho proteins in
human monocytes49, we aimed at studying the effects of
lenalidomide on RhoU expression. Immunoblot analysis
showed an increase in STAT3 activation after treatment
with lenalidomide (Fig. 5b) without a clear effect in via-
bility in U266 (Fig. 5c) and in INA-6 (Supplementary
Figure S2a) cell lines. We also observed an increase in
RhoU expression and in JNK activating phosphorylation
(Fig. 5b and Supplementary Figure S2a) that could result
in increased cell mobility. When combining RhoU inhi-
bition with lenalidomide we observed that JNK phos-
phorylation remained unchanged instead of increasing as
happened in UN and SCR conditions (Fig. 5d). When
comparing siRNA and SCR transfected cells we observed
a signiﬁcant decrease in migration (Fig. 5e and f). RhoU is
thus essential for JNK activation and MM cell migration.
Treatment with lenalidomide, that consequently deter-
mined higher RhoU and active JNK levels, resulted in a
boost in cell migration (Fig. 5e and f; and Supplementary
Figure S2b and c). RhoU silencing abolished lenalidomide
induced migration (Fig. 5e and f).
We further studied cytoskeleton changes and alterations
in cell adhesion by employing IF techniques. Although all
cells were able to adhere to polylysine coated glass, the
Fig. 4 In MM cell lines RHOU expression lays downstream of STAT3 activation. a Correlation between RHOU expression and STAT3 expression
(Pearson’s r = 0.2739; p-value = 0.0017) or MIR21 expression (Pearson’s r = 0.3299; p-value = 0.0001) or SOCS3 expression (Pearson’s r = 0.4988; p-value
= 1.786e-09). b Bar charts showing the percentage of live cells (AnnV−) after treatment with different doses of Stattic. c Bar charts showing RHOU
expression after STAT3 inhibition before and after IL-6 stimulus. Black bars represent RHOU expression after 6 h of culture with different
concentrations of stattic. Grey bars show RHOU expression after 5 h of stattic treatment + 1 h of combined treatment with IL-6 stimulus. *Compared
with same treatment conditions without IL-6 stimulus, #Compared to UN. d Bar charts exhibiting normalized mean cell count ± SD of four samples
from at least two independent experiments, after treatment with increasing concentrations of stattic, accessed by migration assay with IL-6,
normalized over mean migration of UN. b, c, and d UN untreated; student’s t test: NS non signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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changes in cell morphology were evident. SCR cells dis-
played a normal round-up morphology (3D view) with
smooth edges and few spiky protrusions (bottom layer
view); siRNA RhoU cells had bigger lamellipodia-like
edges with an accumulation of stress ﬁbers and focal
adhesions; lenalidomide treated SCR cells were ﬂattened
(3D view) and with multiple ﬁlopodial protrusion (bottom
layer view), typical of migrating cells in accordance with
the migration data above; noteworthy, the combination of
RhoU silencing with lenalidomide treatment resulted in a
loss of cytoskeleton organization (Fig. 5g).
To deepen the study of STAT3 activation and RhoU
overexpression upon lenalidomide treatment, we have
analyzed the expression of STAT3 itself and its target
genes MIR21, SOCS3 and RHOU in a GEP dataset of
OPM2 cell line upon lenalidomide treatment for 48 and
72 h (#GSE31421)50. Upon lenalidomide treatment there
is a 50% increase in STAT3 expression, while the increase
in the expression of its target genes is even more clear
(Fig. 5h).
Additionally, since RhoU silencing caused cell cycle
arrest we further investigated the changes in cell cycle
after lenalidomide treatment or the combination of both.
Twenty four-hour treatment with lenalidomide caused a
signiﬁcant increase in G0/G1 phase and a decrease in S
phase (Fig. 6a). The combination of both RhoU silencing
and lenalidomide led to a further accumulation of cells in
the G0/G1 phase (Fig. 6a). We have also analyzed cyclin
D2 expression, unraveling that although lenalidomide
treatment impaired the transition from G1 to S phases, it
did have a signiﬁcant impact in cyclin D2 expression (Fig.
6b). However, as previously described in literature, lena-
lidomide treatment caused an increase in p21 expres-
sion51 in both conditions that might explain the
impairment in cell cycle progression.
A schematic view of the proposed mechanism is
depicted in Fig. 6c.
Discussion
We report here the ﬁrst evidence of a clear unbalance in
the expression of multiple members of the Rho GTPase
family in MM PCs when compared to normal PCs.
Interestingly, opposite to what was seen in other tumors
where there is an over-expression of some of the members
of this family7, we have found that more than 50% of Rho
GTPases are actually down-modulated in MM PCs when
compared to healthy PCs.
Focusing our attention on the RhoU/V family, we have
found that RhoU expression is signiﬁcantly modulated
during the different steps of MM progression. MGUS
patients showed higher RhoU levels when compared to
normal controls, raising the hypothesis that this protein
might be important especially in the early stages of MM
malignancy. With disease progression and accumulation
of malignant PCs in the BM, we observed a decrease in
RHOU when compared to MGUS patients. It has been
reported that high RhoU levels lead to enhanced cell
motility, while low RhoU levels are essential for adhe-
sion47. It is predictable that RhoU is expressed at high
levels in the initial steps of the disease when PCs could be
more motile since they are competing for BM niches52.
With disease progression inside the BM, cells adhere and
rely on the microenvironment for their survival, which
seems to translate in a cell-contact dependent decrease in
RHOU expression, hypothesis supported by the in vitro
evidence of a RHOU down-modulation in MM cell lines
cultured in contact with HS-5 stromal cells.
Remarkably, MM patients in high risk TC groups have
signiﬁcantly higher levels of RHOU mRNA that positively
correlated with the presence of unfavorable cytogenetic
alterations; however the sole presence of 1q gain, where
RHOU gene is located, was not enough to cause a sig-
niﬁcant change in its expression. Also, higher levels of
RHOU expression correlated with increased CCND2 and
decreased cell cycle control and DNA damage repair
Fig. 5 Lenalidomide enhances MM cell migration through the upregulation of RhoU. a Immunoblot of U266 proteins and bar chart exhibiting
normalized mean cell count ± SD of four samples from at least two independent experiments, after 24 h of transfection with SCR or RhoU siRNA. b
Immunoblots of U266 proteins after 4 and 24 h of treatment with different doses of lenalidomide. c Bar charts showing the percentage of live cells
(AnnV−) after treatment with different doses of lenalidomide for 24 h. d Immunoblot of U266 proteins after 48 h of transfection with RhoU or SCR
siRNA, lenalidomide was added in the last 24 h. a, b, and d show representative immunoblots from six samples from at least two independent
experiments; UN untreated, NT not transfected; protein expression is showed in the following order: RhoU, phospho-STAT3(Tyr705), STAT3, phospho-
JNK(Thr183/Tyr185), and GAPDH. e Bar charts showing normalized mean cell count ± SD of four samples from at least two independent experiments
after 48 h of transfection with RhoU or SCR siRNA combined with lenalidomide treatment in the last 24 h accessed by migration assay with IL-6,
normalized over mean migration of UN. f Bar charts showing normalized mean cell count ± SD of four samples from at least two independent
experiments after 48 h of transfection with RhoU or SCR siRNA combined with lenalidomide treatment in the last 24 h accessed by migration assay
with MSC medium, normalized over mean migration of UN. e and f UN untreated *Compared to UN; #compared to SCR; £compared to SCR + Lena,
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. g Changes in the actin cytoskeleton after RhoU silencing or SCR transfection combined or not with
lenalidomide treatment. DAPI staining shows the nucleus in blue, phalloidin staining in red shows F-actin ﬁlaments. Cells were ﬁxed after 48 h siRNA
transfection and 24 h of 5 μM lenalidomide treatment. All cells were plated at the same concentration in a six well plate for 48 h to maintain growth
conditions. h Expression of STAT3 and its targets MIR21, SOCS3, and RHOU after treatment of OPM2 cell line with lenalidomide for 48 and 72 h
(#GSE31421)
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genes; while RhoU silencing resulted in a decrease in
cyclin D2 protein expression and impaired cell cycle
progression. Put together, these results suggest that even
though most MM patients down-modulate RHOU with
disease progression, a high expression of this GTPase in
late stages of this malignancy could actually be associated
with a worse prognosis. We also found that IL-6 stimulus,
important for MM survival, resulted in a STAT3-
dependent increase in RHOU expression in cell lines.
Likewise, CD45+ U266 cells, that have increased JAK/
STAT activation45,46,, exhibited a 2.3 times higher MFI for
intracytoplasmic RhoU staining. To note, in MM patients
RHOU expression correlated with the expression of
STAT3 itself, of MIR21 and of SOCS3, conﬁrming that it
might be highly dependent on the activation of the
STAT3 cascade, as observed in MM cell lines.
RhoU silencing led to a loss of migration capability
probably due to the decrease in active JNK, as previous
studies suggested: a constitutively active RhoU mutant
was able to increase JNK activation in mouse epithelial
cells53 and RhoU depletion in HelaS3 cells inhibited JNK
activating phosphorylation consequently impairing ﬁlo-
podium formation, a type of cell protrusion essential for
cell migration54. Lastly, we described the effects of IMIDs
on the IL-6/STAT3/RhoU/JNK branch. This new gen-
eration drugs for MM treatment have been shown to
reorganize cells’ cytoskeleton by modulating Rho GTPa-
ses in human monocytes49. Indeed, we found that lenali-
domide commanded an increased activation of STAT3,
augmented RhoU expression and ampliﬁed JNK phos-
phorylation. Parallel to the changes in cytoskeleton con-
formation after lenalidomide, we also observed a decrease
in cell cycle progression, probably through a p21 depen-
dent mechanism, in line with what is already known for
this drug51,55,56,. Consistently and opposite to what was
observed with RhoU silencing, lenalidomide led to a high
increase in cell motility. The combination of RhoU
silencing with lenalidomide treatment led to a loss of
cytoskeleton organization that translated in a defective
migratory capability, and a further increase in cell cycle
arrest. These results give insights into a novel mechanism
of action of lenalidomide and prove that this drug can
somehow stimulate the activation of STAT3 transcription
factor enhancing the expression of its target genes
including RHOU, leading to cytoskeletal changes in MM
PCs. The increased cell motility upon lenalidomide is
consistent with the disruption of microenvironment niche
previously described57,58, where less adherent cells are
more easily targeted by immune cells or combined che-
motherapeutics. Nevertheless, whether or not high RhoU
levels indicate an increased propensity towards dis-
semination of malignant PCs, whether RhoU levels during
lenalidomide therapy in MM patients are increased, and
whether RhoU high-expressing MM could display differ-
ent responsiveness to lenalidomide remains to be clariﬁed.
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Fig. 6 Cell cycle analysis and schematic view of the effect of lenalidomide, RhoU silencing or their combination in MM cells. a Cell cycle
analysis based on PI staining of SCR and siRNA RHOU cells 48 h after transfection with the addition of lenalidomide in the last 24 h. Data represents
mean ± SD of three independent experiments. Student’s t test: *SCR compared to SCR + Lena; #siRNA RhoU compared to siRNA RhoU + Lena; £siRNA
RhoU + Lena compared to SCR + Lena, *p < 0.05; **p < 0.01. b Representative immunoblots from six samples from at least two independent
experiments of RhoU, cyclin D2, and p21 expression after siRNA transfection and lenalidomide treatments, and densitometry of the expression of
cyclin D2/GAPDH. c Lenalidomide treatment determines an increase in STAT3 activation and consequently the increased expression of STAT3 target
genes including RhoU. This, combined with increased levels of pJNK, results in a reorganization of the cytoskeleton and boosts cell migration. These
effects are parallel to cell cycle arrest, through a mechanism that is not explored in this manuscript. RhoU inhibition, on the other hand, results in
decreased levels of active JNK leading to decreased cell migration rates and increased lamellipodial protrusions. RhoU silencing also caused MM cell
cycle arrest due to a decrease in the expression of cyclin D2. The combination of both RhoU silencing and lenalidomide treatment further inhibits cell
cycle progression and overcomes lenalidomide induced migration by decreasing the levels of active JNK causing however a loss of cytoskeleton
organization. This cytoskeleton organization loss may be due to the expression of other STAT3 target genes or due to lenalidomide targets not
explored in this article
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